Posted: October 20, 2021 at 3:02 p.m. CDT|Update: 13 minutes ago
Pennington, New Jersey and SAN DIEGO, 20 October 2021 / PRNewswire / – OncoSec Medical Incorporated (NASDAQ: ONCS) (the âCompanyâ or âOncoSecâ), a clinical-stage biotechnology company focused on the development of intratumoral cytokine-based immunotherapies to stimulate the body’s immune system in order to target and attack cancer, announced today that Chris twitty, Ph.D., Scientific Director, will step down to pursue a new opportunity with a private oncology company.
Marguerite Dalesandro, Ph.D., Chairman of the Board of Directors and Member of the Management Committee of OncoSec, said: âOn behalf of the Board of Directors and the other members of the Management Committee, we thank Dr. Twitty for led the OncoSec project. team over the past five years and we thank him for his contribution to our significant progress towards bringing TAVO to patients. “
Sandra Aung, Ph.D., Director of Clinical Development, added, âWe continue to be encouraged by the maturation data from the KEYNOTE-695 study and look forward to working with health authorities on what we believe is a therapy. effective for those patients with no standard care options. “
The formal analysis of KEYNOTE-695 and the first results of the primary endpoint, overall response rate (ORR) by independent central blinded examination (BICR) based on RECIST, will be announced in the first quarter of 2022.
Updated data from TAVO â¢ from the KEYNOTE-695 clinical trial will be available at 7:00 am EST on Friday, November 12, 2021, in a poster presentation to the Society for Immunotherapy of Cancer (SITC) 36e Annual meeting at Washington DC The SITC poster presentation is No.383, titled: ‘Durable responses with intratumoral electroporation of the interleukin 12 plasmid plus pembrolizumab in patients with advanced melanoma evolving on anti-PD-1 antibody: updated data from Keynote 695. ‘ OncoSec will make the poster presentation available on its website after publication at SITC 2021 and host a SITC KOL Symposium webinar on 12 november To 7:00 a.m. EST for SITC participants and investors. Please click here to register for the webinar.
Dr. Herbert Kim Lyerly, duke university School of Medicine, OncoSec Board of Directors and Member of the Executive Committee, added: âAs an oncologist specializing in intra-tumor cytokine immunotherapies, TAVO â¢ is an active drug with a profile of remarkable safety, which will be useful to a patient refractory to PD-1. population for which there are no approved therapies. We are excited to update the community at SITC 2021. “
There will also be updated TAVO â¢ data from the ongoing KEYNOTE-890 clinical trial at the 2021 San Antonio Breast Cancer Symposium (SABCS), December 7-10, 2021, in a poster presentation summary # 2196, titled: “Ongoing trial: phase 2 study of the intratumoral plasmid interleukin-12 (tavokinogene telseplasmid; TAVO â¢) plus electroporation in combination with pembrolizumab with or without chemotherapy in patients with locally advanced or inoperable metastatic triple negative breast cancer ( KEYNOTE-890 / OMS -I141). ‘ OncoSec will make the poster available on its website after its publication at SABCS 2021.
Finally, with regard to the search for CEOs, the Board of Directors continues to meet high quality candidates and expects to appoint a new CEO in the near term.
About OncoSec Medical Incorporated
OncoSec Medical Incorporated (the “Company”, “OncoSec”, “we” or “our”) is a biotechnology company focused on the development of intratumoral cytokine-based immunotherapies to stimulate the body’s immune system to target and ‘attack cancer. OncoSec’s leading immunotherapy research product candidate – TAVO â¢ (tavokinogenic tilseplasmid) – enables intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune stimulating functions. The technology, which uses electroporation, is designed to produce controlled and localized expression of IL-12 in the tumor microenvironment, allowing the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline using TAVO â¢ as a potential treatment for multiple cancer indications, either as monotherapy or in combination with leading checkpoint inhibitors; the latter potentially allowing OncoSec to meet a major unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO â¢ have demonstrated a local immune response, and subsequently, a systemic effect as a single therapy approach or in combination with an acceptable safety profile, warranting further development. In addition to TAVO â¢, OncoSec identifies and develops new DNA coded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to target deep visceral lesions, such as liver, lung or pancreatic lesions . For more information, please visit www.oncosec.com.
TAVO â¢ is a trademark of OncoSec Medical Incorporated.
View original content to download multimedia:
SOURCE OncoSec Medical Incorporated
The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.